# PeptideScanner evidence objects: Tesofensine

Every published version of the records placed with Tesofensine, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/tesofensine.json. Selected public evidence only; not medical advice.

- Objects: 11
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00006077-tesofensine-v1"></a>

## ClinicalTrials.gov record NCT00006077

> PeptideScanner retained ClinicalTrials.gov record NCT00006077 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was tesofensine.

- Evidence object: `story:clinicaltrials-gov-nct00006077-tesofensine:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-03-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00006077-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct00006077-tesofensine-v1
- Content SHA-256: `794389637636c21372726443c3e639d6579350e93c34dfe28c6de7711e823897`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00006077 ([`ctg-observation-nct00006077-2008-03-04-bfc2ad48e44c`](#source-ctg-observation-nct00006077-2008-03-04-bfc2ad48e44c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00006077 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct00006077-2008-03-04-bfc2ad48e44c`](#source-ctg-observation-nct00006077-2008-03-04-bfc2ad48e44c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00006077 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct00006077-2008-03-04-bfc2ad48e44c`](#source-ctg-observation-nct00006077-2008-03-04-bfc2ad48e44c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00006077-2008-03-04-bfc2ad48e44c`](#source-ctg-observation-nct00006077-2008-03-04-bfc2ad48e44c))

### Sources

<a id="source-ctg-observation-nct00006077-2008-03-04-bfc2ad48e44c"></a>
- **ClinicalTrials.gov record NCT00006077 · retained source version 2008-03-04:bfc2ad48e44cf6ce3c25fcc4df1d42ff15839d86dd61ad54dee6c51da39367a1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00006077) (`ctg-observation-nct00006077-2008-03-04-bfc2ad48e44c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00006077." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct00006077-tesofensine-v1 SHA-256: 794389637636c21372726443c3e639d6579350e93c34dfe28c6de7711e823897.

---

<a id="clinicaltrials-gov-nct00394667-tesofensine-v1"></a>

## ClinicalTrials.gov record NCT00394667

> PeptideScanner retained ClinicalTrials.gov record NCT00394667 at 2026-11-16T17:29:46.323Z. Its registry update date was 2013-04-22, and PeptideScanner's reviewed identity mapping was tesofensine.

- Evidence object: `story:clinicaltrials-gov-nct00394667-tesofensine:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-04-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00394667-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct00394667-tesofensine-v1
- Content SHA-256: `58ca312befe9adcc085412789d4d7cb34ac42d86ad3203415164b35d072bab33`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00394667 ([`ctg-observation-nct00394667-2013-04-22-23740f6bc971`](#source-ctg-observation-nct00394667-2013-04-22-23740f6bc971))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00394667 at 2026-11-16T17:29:46.323Z. Its registry update date was 2013-04-22, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct00394667-2013-04-22-23740f6bc971`](#source-ctg-observation-nct00394667-2013-04-22-23740f6bc971))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00394667 at 2026-11-16T17:29:46.323Z. Its registry update date was 2013-04-22, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct00394667-2013-04-22-23740f6bc971`](#source-ctg-observation-nct00394667-2013-04-22-23740f6bc971))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00394667-2013-04-22-23740f6bc971`](#source-ctg-observation-nct00394667-2013-04-22-23740f6bc971))

### Sources

<a id="source-ctg-observation-nct00394667-2013-04-22-23740f6bc971"></a>
- **ClinicalTrials.gov record NCT00394667 · retained source version 2013-04-22:23740f6bc971aaad5176bba9f9531c0693806f0153ab9267688789ec4ffd3ced** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00394667) (`ctg-observation-nct00394667-2013-04-22-23740f6bc971`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00394667." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct00394667-tesofensine-v1 SHA-256: 58ca312befe9adcc085412789d4d7cb34ac42d86ad3203415164b35d072bab33.

---

<a id="clinicaltrials-gov-nct00428415-tesofensine-v1"></a>

## ClinicalTrials.gov record NCT00428415

> PeptideScanner retained ClinicalTrials.gov record NCT00428415 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-05, and PeptideScanner's reviewed identity mapping was tesofensine.

- Evidence object: `story:clinicaltrials-gov-nct00428415-tesofensine:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-03-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00428415-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct00428415-tesofensine-v1
- Content SHA-256: `a9251b8dcb9b40623a58b6a06306628be04976f2471ebe93d4283daa5095a22e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00428415 ([`ctg-observation-nct00428415-2008-03-05-4e496e834271`](#source-ctg-observation-nct00428415-2008-03-05-4e496e834271))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00428415 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-05, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct00428415-2008-03-05-4e496e834271`](#source-ctg-observation-nct00428415-2008-03-05-4e496e834271))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00428415 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-05, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct00428415-2008-03-05-4e496e834271`](#source-ctg-observation-nct00428415-2008-03-05-4e496e834271))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00428415-2008-03-05-4e496e834271`](#source-ctg-observation-nct00428415-2008-03-05-4e496e834271))

### Sources

<a id="source-ctg-observation-nct00428415-2008-03-05-4e496e834271"></a>
- **ClinicalTrials.gov record NCT00428415 · retained source version 2008-03-05:4e496e834271649025e17fdfbb047db9af1d075bddbba6228167ae1d7b130492** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00428415) (`ctg-observation-nct00428415-2008-03-05-4e496e834271`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00428415." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct00428415-tesofensine-v1 SHA-256: a9251b8dcb9b40623a58b6a06306628be04976f2471ebe93d4283daa5095a22e.

---

<a id="clinicaltrials-gov-nct00481104-tesofensine-v1"></a>

## ClinicalTrials.gov record NCT00481104

> PeptideScanner retained ClinicalTrials.gov record NCT00481104 at 2026-11-16T17:29:46.323Z. Its registry update date was 2011-07-04, and PeptideScanner's reviewed identity mapping was tesofensine.

- Evidence object: `story:clinicaltrials-gov-nct00481104-tesofensine:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-07-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00481104-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct00481104-tesofensine-v1
- Content SHA-256: `83c6bae12d97b5bc060ad6f46ad7af7560e6c871337576c6127e150b31afa234`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00481104 ([`ctg-observation-nct00481104-2011-07-04-d9da54defab7`](#source-ctg-observation-nct00481104-2011-07-04-d9da54defab7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00481104 at 2026-11-16T17:29:46.323Z. Its registry update date was 2011-07-04, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct00481104-2011-07-04-d9da54defab7`](#source-ctg-observation-nct00481104-2011-07-04-d9da54defab7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00481104 at 2026-11-16T17:29:46.323Z. Its registry update date was 2011-07-04, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct00481104-2011-07-04-d9da54defab7`](#source-ctg-observation-nct00481104-2011-07-04-d9da54defab7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00481104-2011-07-04-d9da54defab7`](#source-ctg-observation-nct00481104-2011-07-04-d9da54defab7))

### Sources

<a id="source-ctg-observation-nct00481104-2011-07-04-d9da54defab7"></a>
- **ClinicalTrials.gov record NCT00481104 · retained source version 2011-07-04:d9da54defab771f670ee27e2708e6211d99fe4540aad27f6d3f66b4d89148425** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00481104) (`ctg-observation-nct00481104-2011-07-04-d9da54defab7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00481104." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct00481104-tesofensine-v1 SHA-256: 83c6bae12d97b5bc060ad6f46ad7af7560e6c871337576c6127e150b31afa234.

---

<a id="clinicaltrials-gov-nct02737891-tesofensine-v1"></a>

## ClinicalTrials.gov record NCT02737891

> PeptideScanner retained ClinicalTrials.gov record NCT02737891 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine.

- Evidence object: `story:clinicaltrials-gov-nct02737891-tesofensine:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-05-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02737891-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct02737891-tesofensine-v1
- Content SHA-256: `22184bd7dacaf389728ab20519d79b1963e5633bbec7441dfd7696f5654323ac`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02737891 ([`ctg-observation-nct02737891-2020-05-14-845ff8c8d2a7`](#source-ctg-observation-nct02737891-2020-05-14-845ff8c8d2a7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02737891 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct02737891-2020-05-14-845ff8c8d2a7`](#source-ctg-observation-nct02737891-2020-05-14-845ff8c8d2a7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02737891 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct02737891-2020-05-14-845ff8c8d2a7`](#source-ctg-observation-nct02737891-2020-05-14-845ff8c8d2a7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02737891-2020-05-14-845ff8c8d2a7`](#source-ctg-observation-nct02737891-2020-05-14-845ff8c8d2a7))

### Sources

<a id="source-ctg-observation-nct02737891-2020-05-14-845ff8c8d2a7"></a>
- **ClinicalTrials.gov record NCT02737891 · retained source version 2020-05-14:845ff8c8d2a70bec06db5592680ccbc4e9e9b8e982df2b5e72249edde4008671** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02737891) (`ctg-observation-nct02737891-2020-05-14-845ff8c8d2a7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02737891." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct02737891-tesofensine-v1 SHA-256: 22184bd7dacaf389728ab20519d79b1963e5633bbec7441dfd7696f5654323ac.

---

<a id="clinicaltrials-gov-nct03149445-tesofensine-v1"></a>

## ClinicalTrials.gov record NCT03149445

> PeptideScanner retained ClinicalTrials.gov record NCT03149445 at 2026-11-16T17:29:46.323Z. Its registry update date was 2024-02-26, and PeptideScanner's reviewed identity mapping was tesofensine.

- Evidence object: `story:clinicaltrials-gov-nct03149445-tesofensine:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-02-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03149445-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct03149445-tesofensine-v1
- Content SHA-256: `88de05a0b3f17803222ed0924b876f4af0fb36da2b11c6675fb2916e98beed1a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03149445 ([`ctg-observation-nct03149445-2024-02-26-00979aa158e1`](#source-ctg-observation-nct03149445-2024-02-26-00979aa158e1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03149445 at 2026-11-16T17:29:46.323Z. Its registry update date was 2024-02-26, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct03149445-2024-02-26-00979aa158e1`](#source-ctg-observation-nct03149445-2024-02-26-00979aa158e1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03149445 at 2026-11-16T17:29:46.323Z. Its registry update date was 2024-02-26, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct03149445-2024-02-26-00979aa158e1`](#source-ctg-observation-nct03149445-2024-02-26-00979aa158e1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03149445-2024-02-26-00979aa158e1`](#source-ctg-observation-nct03149445-2024-02-26-00979aa158e1))

### Sources

<a id="source-ctg-observation-nct03149445-2024-02-26-00979aa158e1"></a>
- **ClinicalTrials.gov record NCT03149445 · retained source version 2024-02-26:00979aa158e14135fd25e2de9993251f0216ccd72a5b19fff1cf475e407a3a20** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03149445) (`ctg-observation-nct03149445-2024-02-26-00979aa158e1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03149445." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct03149445-tesofensine-v1 SHA-256: 88de05a0b3f17803222ed0924b876f4af0fb36da2b11c6675fb2916e98beed1a.

---

<a id="clinicaltrials-gov-nct03286829-tesofensine-v1"></a>

## ClinicalTrials.gov record NCT03286829

> PeptideScanner retained ClinicalTrials.gov record NCT03286829 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine.

- Evidence object: `story:clinicaltrials-gov-nct03286829-tesofensine:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-05-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03286829-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct03286829-tesofensine-v1
- Content SHA-256: `89221ca84d8024df2af082847aa565cf5359065f03cbdf9361fb68e23ef44896`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03286829 ([`ctg-observation-nct03286829-2020-05-14-e952543454a0`](#source-ctg-observation-nct03286829-2020-05-14-e952543454a0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03286829 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct03286829-2020-05-14-e952543454a0`](#source-ctg-observation-nct03286829-2020-05-14-e952543454a0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03286829 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine. ([`ctg-observation-nct03286829-2020-05-14-e952543454a0`](#source-ctg-observation-nct03286829-2020-05-14-e952543454a0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03286829-2020-05-14-e952543454a0`](#source-ctg-observation-nct03286829-2020-05-14-e952543454a0))

### Sources

<a id="source-ctg-observation-nct03286829-2020-05-14-e952543454a0"></a>
- **ClinicalTrials.gov record NCT03286829 · retained source version 2020-05-14:e952543454a0416a5eba6cb8b05792880a499901a40b68e91c0cc08e4c7a7ab2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03286829) (`ctg-observation-nct03286829-2020-05-14-e952543454a0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03286829." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#clinicaltrials-gov-nct03286829-tesofensine-v1 SHA-256: 89221ca84d8024df2af082847aa565cf5359065f03cbdf9361fb68e23ef44896.

---

<a id="pubmed-pmid-17324246-tesofensine-v1"></a>

## Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.

> PubMed lists PMID 17324246 in British journal of clinical pharmacology as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-02-23 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17324246-tesofensine:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17324246-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#pubmed-pmid-17324246-tesofensine-v1
- Content SHA-256: `19c0b468bc5f735c8444efd524ca16a81c26c4b27d9bedc23ff3e0c6bedee269`

### Claims and source pins

#### Headline

Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. ([`pubmed-observation-pmid-17324246-2018-11-13-d2a8f008a394`](#source-pubmed-observation-pmid-17324246-2018-11-13-d2a8f008a394))

#### Summary

PubMed lists PMID 17324246 in British journal of clinical pharmacology as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-02-23 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17324246-2018-11-13-d2a8f008a394`](#source-pubmed-observation-pmid-17324246-2018-11-13-d2a8f008a394))

#### Paragraph 1

PubMed lists PMID 17324246 in British journal of clinical pharmacology as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-02-23 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17324246-2018-11-13-d2a8f008a394`](#source-pubmed-observation-pmid-17324246-2018-11-13-d2a8f008a394))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17324246-2018-11-13-d2a8f008a394`](#source-pubmed-observation-pmid-17324246-2018-11-13-d2a8f008a394))

### Sources

<a id="source-pubmed-observation-pmid-17324246-2018-11-13-d2a8f008a394"></a>
- **Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. · retained source version 1:2018-11-13:current:d2a8f008a394d0082b9a23b921fbfeedbf6b1ca7a2ae58d5b04ac9401ad2a830** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17324246/) (`pubmed-observation-pmid-17324246-2018-11-13-d2a8f008a394`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#pubmed-pmid-17324246-tesofensine-v1 SHA-256: 19c0b468bc5f735c8444efd524ca16a81c26c4b27d9bedc23ff3e0c6bedee269.

---

<a id="pubmed-pmid-17982477-tesofensine-v1"></a>

## Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.

> PubMed lists PMID 17982477 in British journal of pharmacology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-11-05 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17982477-tesofensine:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17982477-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#pubmed-pmid-17982477-tesofensine-v1
- Content SHA-256: `de7f2cd3c3ba340b34b99610643ca9a1ddec5278c605dc167ca8c09a74863741`

### Claims and source pins

#### Headline

Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. ([`pubmed-observation-pmid-17982477-2021-10-20-7dbcf0e2e522`](#source-pubmed-observation-pmid-17982477-2021-10-20-7dbcf0e2e522))

#### Summary

PubMed lists PMID 17982477 in British journal of pharmacology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-11-05 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17982477-2021-10-20-7dbcf0e2e522`](#source-pubmed-observation-pmid-17982477-2021-10-20-7dbcf0e2e522))

#### Paragraph 1

PubMed lists PMID 17982477 in British journal of pharmacology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-11-05 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17982477-2021-10-20-7dbcf0e2e522`](#source-pubmed-observation-pmid-17982477-2021-10-20-7dbcf0e2e522))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17982477-2021-10-20-7dbcf0e2e522`](#source-pubmed-observation-pmid-17982477-2021-10-20-7dbcf0e2e522))

### Sources

<a id="source-pubmed-observation-pmid-17982477-2021-10-20-7dbcf0e2e522"></a>
- **Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. · retained source version 1:2021-10-20:current:7dbcf0e2e522bc2c0d15a2f63fecbba504d75e38c3c73320992b75eddf2114a3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17982477/) (`pubmed-observation-pmid-17982477-2021-10-20-7dbcf0e2e522`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#pubmed-pmid-17982477-tesofensine-v1 SHA-256: de7f2cd3c3ba340b34b99610643ca9a1ddec5278c605dc167ca8c09a74863741.

---

<a id="pubmed-pmid-19705923-tesofensine-v1"></a>

## A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

> PubMed lists PMID 19705923 in Clinical pharmacokinetics as Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19705923-tesofensine:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19705923-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#pubmed-pmid-19705923-tesofensine-v1
- Content SHA-256: `828d98820136046bda862d76f0e9bdeb5ce29e814c919d4a3d6e472f2a14968a`

### Claims and source pins

#### Headline

A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. ([`pubmed-observation-pmid-19705923-2021-10-20-6ca15a400765`](#source-pubmed-observation-pmid-19705923-2021-10-20-6ca15a400765))

#### Summary

PubMed lists PMID 19705923 in Clinical pharmacokinetics as Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19705923-2021-10-20-6ca15a400765`](#source-pubmed-observation-pmid-19705923-2021-10-20-6ca15a400765))

#### Paragraph 1

PubMed lists PMID 19705923 in Clinical pharmacokinetics as Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19705923-2021-10-20-6ca15a400765`](#source-pubmed-observation-pmid-19705923-2021-10-20-6ca15a400765))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19705923-2021-10-20-6ca15a400765`](#source-pubmed-observation-pmid-19705923-2021-10-20-6ca15a400765))

### Sources

<a id="source-pubmed-observation-pmid-19705923-2021-10-20-6ca15a400765"></a>
- **A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. · retained source version 1:2021-10-20:current:6ca15a4007650983c8047cd3e6ad8747d419aabb38f444f738d9d60bce71acc4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19705923/) (`pubmed-observation-pmid-19705923-2021-10-20-6ca15a400765`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#pubmed-pmid-19705923-tesofensine-v1 SHA-256: 828d98820136046bda862d76f0e9bdeb5ce29e814c919d4a3d6e472f2a14968a.

---

<a id="pubmed-pmid-42320973-tesofensine-v1"></a>

## Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine.

> PubMed lists PMID 42320973 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-06-19 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42320973-tesofensine:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42320973-tesofensine/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#pubmed-pmid-42320973-tesofensine-v1
- Content SHA-256: `bbf51bcd7e206c7488865357b1ce38d59da9a7f77df170e0dcb50e7bd6c499f7`

### Claims and source pins

#### Headline

Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine. ([`pubmed-observation-pmid-42320973-2026-09-03-9ce603371198`](#source-pubmed-observation-pmid-42320973-2026-09-03-9ce603371198))

#### Summary

PubMed lists PMID 42320973 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-06-19 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42320973-2026-09-03-9ce603371198`](#source-pubmed-observation-pmid-42320973-2026-09-03-9ce603371198))

#### Paragraph 1

PubMed lists PMID 42320973 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-06-19 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42320973-2026-09-03-9ce603371198`](#source-pubmed-observation-pmid-42320973-2026-09-03-9ce603371198))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42320973-2026-09-03-9ce603371198`](#source-pubmed-observation-pmid-42320973-2026-09-03-9ce603371198))

### Sources

<a id="source-pubmed-observation-pmid-42320973-2026-09-03-9ce603371198"></a>
- **Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine. · retained source version 1:2026-09-03:current:9ce603371198019b7cdb9d063b030038b74341a1eb2d5121e8ce44ba2a3ffc47** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42320973/) (`pubmed-observation-pmid-42320973-2026-09-03-9ce603371198`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tesofensine.json#pubmed-pmid-42320973-tesofensine-v1 SHA-256: bbf51bcd7e206c7488865357b1ce38d59da9a7f77df170e0dcb50e7bd6c499f7.

